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Gastric cancer remains a signiﬁcant health problem
worldwide,
1 and yet the progress has been much
slower against gastric cancer than against other can-
cers (colon, breast, lung, and prostate); however, the
other cancers are more common in the West. Reasons
for this discrepancy are many, but it is clear that if a
cancer type is common in the West, it gets attention
from the pharmaceutical companies and the U.S.
Government. Our approach to localized gastric can-
cer has been typical of that for many other localized
cancers; that is, we attempt a good clinical staging
process and treat all deﬁned stages similarly (empir-
icism). Whether we use preoperative therapy, surgery,
or postoperative adjuvant therapy, one thing is cer-
tain: all patients with >T1 cancers when offered
uniform therapy end up with diverse outcomes.
Without much insight, we simply follow our patients
to see who survives and who dies. We also witness
unpredictable and sometime extraordinary toxicities
(complications) experienced by our patients. The
question is how can we possibly get out of this modus
operandi? Recent molecular studies have demon-
strated surprising intertumoral molecular heteroge-
neity that was unexpected, creating even more
challenges than we thought previously.
2 In gastric
cancer, our limited knowledge restricts us even fur-
ther, but it may be time to face that challenge.
ThearticlebyMansouretal.
3providessomecluesas
tohowonecouldpossiblygoaboutthis.Inthisissueof
the Journal, the authors from the Memorial Sloan
Kettering Cancer Center relate their experience in 168
patients with curatively resected gastric cancer who
received various combinations of cytotoxics preoper-
atively (and sometime postoperatively). The authors
systematically examined the resected specimens to
judge the degree of residual cancer and correlated the
degree of ‘‘response’’ to disease-speciﬁc-survival
(DSS). The authors found that the 3-year DSS was
signiﬁcantly different in the univariate but not in the
multivariate analysis. No overall survival correlations
are stated, and I am assuming that none existed. They
observed that the presence of metastatic lymph nodes
and perineural invasion were independently predictive
of DSS in the multivariate analysis. The authors con-
clude that prediction and prognostication in patients
with localized gastric cancer are complicated, and one
may have to lean on multiple parameters (clinical and
biologic) to make advances.
There are many issues worth pondering. Clearly,
studies in esophageal cancer have taught us a great
deal,
4–8 and some studies in gastric cancer
9–13 seem to
showsimilarresults.Tounderstandthissuccinctly,one
must recognize that all the elements of heterogeneous
clinical biologic expressions are embodied in the pri-
mary cancer, and these manifest based on the level of
injury one inﬂicts on it. Chemotherapy is less likely to
lead to a manifestation of a higher level of heteroge-
neity compared with chemoradiation therapy (this is
well known in esophageal and gastric cancers). As in
the Mansour et al. study, and there are numerous
examples published already; the most recent is one by
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14 showing that the rate of pathologic
complete response (pathCR) or even substantial re-
sponse (1–50% residual cancer) is low with chemo-
therapy alone compared with chemoradiation. I
believethismightbeonereasonMonsouretal.didnot
see substantial correlation between patient outcome
and residual cancer in the surgical specimen. The rate
of pathCR is higher when one uses preoperative
chemoradiation in esophageal cancers
5–7,14 or gastric
cancer
9–11 than when chemotherapy is used. This
meansthatamorepotenttherapyseemstouncoverthe
true nature of clinical biology of the gastric cancer
better than a less potent therapy. When that happens,
we begin to see the correlation between the degree of
residual cancer and patient outcome.
4,6,9–11,15
I agree with Mansour et al. that we should explore
new ways to predict response. Positron emission
tomography (PET) is one method, but there are
considerable limitations of PET in gastric cancer.
Nearly 45% of the cancers are not PET-avid,
16 and
10% of the time, the fundus may have physiologic
(false-positive) PET uptake (that may complicate
interpretations). Thus the number of patients we can
work with remains less than optimum and, therefore,
creates another challenge. However, more speciﬁc
imaging studies (evaluating proliferation, apoptosis,
or oxygenation) might prove useful in this setting. In
addition, studying the cancer biology might allow us
to individualize therapy and follow-up.
Preoperative therapy strategy has been around for a
long time,
17–19 but it is only now that we are seeing
some of the results of prospective evaluation,
20,21 and
the strategy needs considerable reﬁnements and up-
grades. Clearly, the preoperative chemoradiation ap-
proach presents itself as a worthy preoperative
strategy to be compared with preoperative chemo-
therapy alone or with postoperative chemoradiation.
The positive results from some preoperative and
postoperative approaches
20–23 have created an
excitement as well as some confusion. The NCCN
guideline (www.nccn.org) for localized gastric cancer
has taken the position to accept surgery as primary
therapy (to allow for postoperative adjuvant che-
moradiotherapy or enrollment into the ongoing clin-
ical trial) or preoperative approach (when the
multidisciplinary infrastructure is in place). In con-
trast, in the countries where gastric cancer is common
(Japan, Korea, Chile, Peru, China, etc.), the preop-
erative approach is not practiced and postoperative
therapy is not a standard. We have a long way to go to
unify our approaches to localized gastric carcinoma.
Finally, the residual cancer after preoperative
chemoradiation can tell us a great deal about the
clinical biology of gastric cancer. It can be a useful
tool to communicate the prediction of patient out-
come with our colleagues, patients, and families but it
can also teach us a great deal about designing
sophisticated trials that might prove beneﬁcial for our
patients. It is time to make noise in support of
adoption of a routine multidisciplinary approach to
localized gastric cancer and to explore gastric cancer
biology.
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